Breaking News, Financial News

Financial Report: Bristol-Myers Squibb 2Q

Revenues up 7% in the quarter driven by Hep C franchise

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb   2Q Revenues: $4.2 billion (+7%) 2Q Loss: $130 million (earnings were $330 million 2Q14) FY Revenues: $8.2 billion (+7%) FY Earnings: $1.1 billion (-17%) Comments: Hepatitis C Franchise revenues were $479 million in the quarter driven by Daclatasvir. Sprycel sales were up 10% to $405 million. Orencia sales were up 15% to $461 million. Eliquis sales were $437 million compared to $171 in 2Q14. Baraclude sales were down 7% to $343 million; the Reyataz Franchise d...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters